Yunlong Liu | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Posted on by ScienceFather

Dr. Yunlong Liu | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

lecturer at Tiangong university, China

Dr. Yunlong Liu is a distinguished structural biologist specializing in transcriptional regulation and nuclear receptor mechanisms. He is currently a Lecturer at Tiangong University, where he contributes to cutting-edge research in biochemistry and molecular biology. His expertise lies in protein structure determination, molecular interactions, and drug discovery, particularly in identifying potent inhibitors for nuclear receptors. With multiple high-impact publications, including Nucleic Acids Research and Cell Discovery, Dr. Liu has established himself as a promising researcher in his field. He has secured national-level research funding and actively contributes to prestigious scientific projects. Recognized for his academic excellence, he has received numerous awards, including the Outstanding Doctoral Dissertation Award and National Ph.D. Scholarship. His work not only advances fundamental biological understanding but also holds potential for therapeutic applications. With a strong foundation in research and teaching, Dr. Liu continues to make significant contributions to the field of structural biology.

Professional Profile

Education

Dr. Yunlong Liu completed his Ph.D. in Biochemistry and Molecular Biology at China Agricultural University in 2023, where he conducted groundbreaking research on structural biology and transcriptional regulation. His doctoral work involved the determination of multiple protein and nucleic acid complex structures, providing critical insights into nuclear receptor function. During his Ph.D., he was recognized for his exceptional academic performance, receiving the Outstanding Doctoral Dissertation Award and National Ph.D. Scholarship. Prior to his doctoral studies, he earned his undergraduate degree from a prestigious institution, excelling in both coursework and research. His academic journey has been marked by a strong emphasis on molecular mechanisms and protein interactions, laying the foundation for his current research. With a solid background in structural biology and biochemistry, Dr. Liu has developed expertise in crystallography, molecular modeling, and drug discovery, positioning him as a leading researcher in his field.

Professional Experience

Dr. Yunlong Liu is currently a Lecturer in the College of Life Sciences at Tiangong University, where he teaches and mentors students in biochemistry and molecular biology. Before this role, he conducted extensive doctoral research at China Agricultural University, focusing on protein structural analysis and transcriptional regulation. His research contributions include the identification of a highly potent nuclear receptor inhibitor and the resolution of multiple protein-DNA complex structures. As a key member of several national research projects, he has played an instrumental role in advancing molecular biology research in China. He has also secured independent research funding, serving as the Principal Investigator for a National Natural Science Foundation of China project. His professional experience extends beyond academia, as his research findings have implications for pharmaceutical development and biomedical sciences. Through his teaching and research, Dr. Liu continues to shape the next generation of scientists while making significant contributions to his field.

Research Interests

Dr. Yunlong Liu’s research focuses on the molecular mechanisms of transcriptional regulation, nuclear receptor functions, and protein-nucleic acid interactions. His work in structural biology involves determining the 3D structures of key biomolecules using advanced crystallography techniques, providing crucial insights into gene regulation and disease pathways. He is particularly interested in studying nuclear receptors and their role in gene expression, with the aim of identifying novel therapeutic targets for metabolic and genetic disorders. His research has led to the discovery of a nuclear receptor inhibitor with significantly enhanced efficacy, highlighting the potential for drug development. Additionally, he explores epigenetic modifications and their structural basis, contributing to the broader understanding of gene regulation. With a strong commitment to advancing biomedical research, Dr. Liu continues to explore new methodologies and collaborative approaches to address fundamental questions in biochemistry and molecular biology.

Awards and Honors

Dr. Yunlong Liu has been widely recognized for his outstanding contributions to structural biology and molecular research. He received the Outstanding Doctoral Dissertation Award from China Agricultural University, an honor granted to only one recipient in his college. His academic excellence also earned him the National Ph.D. Scholarship, where he ranked second in his college. Throughout his career, he has been involved in prestigious research projects funded by national and provincial organizations, including the National Natural Science Foundation of China and the Tianjin Top Scientist Studio Program. His achievements in protein structure determination and transcriptional regulation have led to publications in top-tier journals such as Nucleic Acids Research and Cell Discovery. His early accomplishments include awards in mathematical modeling competitions and national scholarships during his undergraduate studies. With a track record of excellence, Dr. Liu continues to receive accolades for his impactful research and academic contributions.

Conclusion

Dr. Yunlong Liu is a strong candidate for the Best Researcher Award, given his high-impact research, prestigious awards, and leadership in structural biology. His work in transcriptional regulation and nuclear receptors is scientifically significant and widely recognized. Strengthening international collaborations, expanding independent funding, and showcasing mentorship contributions could further elevate his standing.

Publications Top Noted

1. Nucleic Acid-Based Therapies

  • Title: The Progress and Evolving Trends in Nucleic-Acid-Based Therapies
  • Authors: Liu, Y., Wang, C., Fu, X., & Ren, M.
  • Year: 2025
  • Journal: Biomolecules
  • DOI: 10.3390/biom15030376

2. Nucleic Acid Recognition and 6mA Demethylation

  • Title: Structural Basis of Nucleic Acid Recognition and 6mA Demethylation by Caenorhabditis elegans NMAD-1A
  • Authors: Shang, G., Yang, M., Li, M., Ma, L., Liu, Y., Ma, J., Chen, Y., Wang, X., Fan, S., Xie, M., et al.
  • Year: 2024
  • Journal: International Journal of Molecular Sciences
  • DOI: 10.3390/ijms25020686

3. Transcriptional Regulation and Structural Insights

  • Title: Structures of Human TR4LBD–JAZF1 and TR4DBD–DNA Complexes Reveal the Molecular Basis of Transcriptional Regulation
  • Authors: Liu, Y., Ma, L., Li, M., Tian, Z., Yang, M., Wu, X., Wang, X., Shang, G., Xie, M., Chen, Y., et al.
  • Year: 2023
  • Journal: Nucleic Acids Research
  • DOI: 10.1093/nar/gkac1259

4. Molecular Recognition of Nucleosomes

  • Title: Structures of MPND Reveal the Molecular Recognition of Nucleosomes
  • Authors: Yang, M., Li, X., Tian, Z., Ma, L., Ma, J., Liu, Y., Shang, G., Liang, A., Wu, W., Chen, Z.
  • Year: 2023
  • Journal: International Journal of Molecular Sciences
  • DOI: 10.3390/ijms24043368

5. Epigenetic Functions and Nucleic Acid Repair

  • Title: Structural Insights into the Interactions and Epigenetic Functions of Human Nucleic Acid Repair Protein ALKBH6
  • Authors: Ma, L., Lu, H., Tian, Z., Yang, M., Ma, J., Shang, G., Liu, Y., Xie, M., Wang, G., Wu, W., et al.
  • Year: 2022
  • Journal: Journal of Biological Chemistry
  • DOI: 10.1016/j.jbc.2022.101671

6. Protein-DNA Complex and Recognition Mechanisms

  • Title: Crystal Structures of REF6 and Its Complex with DNA Reveal Diverse Recognition Mechanisms
  • Authors: Tian, Z., Li, X., Li, M., Wu, W., Zhang, M., Tang, C., Li, Z., Liu, Y., Chen, Z., Yang, M., et al.
  • Year: 2020
  • Journal: Cell Discovery
  • DOI: 10.1038/s41421-020-0150-6

 

Harry Jarrett | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Posted on by ScienceFather

Dr. Harry Jarrett | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Head of Science and Research at Heights, United Kingdom

Dr. Harry Jarrett is a passionate scientist with a focus on nutritional research, particularly in the context of chronic disease prevention. He believes that optimizing nutrition can significantly reduce the risk of prevalent health issues. With a PhD in Nutritional Sciences from Ulster University and a strong academic background, Dr. Jarrett has combined clinical and research expertise to contribute to the field of nutrition. His work spans various roles, including his current position as Head of Science and Research at Heights, where he leads human intervention trials and drives product development. Additionally, Dr. Jarrett has substantial experience in the medical field, including his work as a COVID-19 Research Laboratory Coordinator during the pandemic. His career is a testament to his commitment to advancing nutrition science and its real-world applications, striving to make significant contributions to improving public health through research and innovation.

Professional Profile

Education

Dr. Jarrett completed his PhD in Nutritional Sciences at the Nutrition Innovation Centre for Food and Health at Ulster University, where he focused on gene-environment interactions in blood pressure and stroke risk. His thesis investigated how riboflavin can lower systolic blood pressure, a significant finding in hypertension research. Prior to his PhD, he earned a Master’s degree in Exercise and Health Sciences from the University of Exeter, with a focus on nutrition’s impact on mental health and neurodegenerative diseases. Dr. Jarrett also completed a Bachelor’s degree in Exercise and Sport Sciences from the University of Exeter, graduating with first-class honors. His academic journey has been marked by strong achievements, including a postgraduate scholarship, distinction profile, and recognition for his contributions to research. Throughout his education, Dr. Jarrett has demonstrated a deep commitment to exploring the intersections between nutrition, health, and disease prevention.

Professional Experience

Dr. Jarrett’s professional experience spans several prestigious institutions and roles. Currently, he serves as Head of Science and Research at Heights, where he is responsible for the strategic direction and execution of research projects, including human intervention trials focused on nutrition and health. He also coordinates the translation of scientific findings into products and marketing strategies. From 2021 to 2024, Dr. Jarrett worked as a COVID-19 Research Laboratory Coordinator at Guy’s and St Thomas’ NHS Trust, where he managed clinical trials during the pandemic and was responsible for writing protocols, securing ethical approvals, and overseeing research quality. He also held a postdoctoral position at the NNEdPro Global Institute for Food and Nutrition Research, where he led investigations into cardiovascular disease risk factors using data from the UK Biobank. Additionally, Dr. Jarrett has contributed to academia by mentoring students and delivering lectures on nutrition and B-vitamin biochemistry.

Research Interests

Dr. Jarrett’s primary research interest lies in the relationship between nutrition and chronic disease prevention, with a particular focus on cardiovascular health and blood pressure regulation. His work has explored how micronutrients, especially B-vitamins like riboflavin, can impact blood pressure and metabolic function, offering new avenues for non-pharmacological interventions. His PhD research focused on understanding gene-environment interactions, specifically how certain genetic variations can influence an individual’s response to nutritional interventions. Dr. Jarrett is also interested in how nutrition can mitigate the effects of age-related diseases, including neurodegenerative conditions and mental health disorders. His ongoing research involves human intervention trials to assess the efficacy of nutritional supplements in improving health outcomes. Additionally, he is involved in investigating large datasets, such as those from the UK Biobank, to uncover insights into the broader epidemiological relationships between diet and health.

Awards and Honors

Dr. Harry Jarrett has received numerous accolades throughout his academic and professional career, reflecting his exceptional research contributions. Notably, he was awarded the Best Poster award at the Federation of American Societies for Experimental Biology (FASEB) conference for his work on folic acid and one-carbon metabolism. He also earned the Broadening Horizons Travel Bursary from Ulster University and a top-ranking young investigator abstract at the British and Irish Hypertension Society conference. Dr. Jarrett’s commitment to research excellence has earned him recognition from his peers and colleagues. His PhD research, published in the American Journal of Clinical Nutrition, has been widely cited and demonstrates his capacity to contribute to significant scientific advancements. Additionally, he has received honors such as the Postgraduate Commendation from the University of Exeter, further acknowledging his academic excellence and dedication to the field of nutrition science.

Conclusion

Dr. Harry Jarrett is a well-rounded and accomplished researcher with a clear impact in the field of nutrition science. His combination of robust academic background, hands-on clinical experience, leadership in research, and commitment to advancing public health makes him a highly suitable candidate for the Best Researcher Award. By enhancing his cross-disciplinary collaborations and expanding the visibility of his research, Dr. Jarrett has the potential to make even greater contributions to the field in the future.

Publications Top Noted

  • The Role of the Gut Microbiome and Probiotics in Sports Performance: A Narrative Review Update

    • Author(s): Harry Jarrett, Sophie Medlin, James C. Morehen
    • Year: 2025
    • Citation: Jarrett H, Medlin S, Morehen JC. The Role of the Gut Microbiome and Probiotics in Sports Performance: A Narrative Review Update. Nutrients. 2025;17(4):690. doi: 10.3390/nu17040690.

  • Survival of Probiotic Bacterial Cells in the Upper Gastrointestinal Tract and the Effect of the Surviving Population on the Colonic Microbial Community Activity and Composition

    • Author(s): Marlies Govaert, Chloë Rotsaert, Chelsea Vannieuwenhuyse, Cindy Duysburgh, Sophie Medlin, Massimo Marzorati, Harry Jarrett
    • Year: 2024
    • Citation: Govaert M, Rotsaert C, Vannieuwenhuyse C, Duysburgh C, Medlin S, Marzorati M, Jarrett H. Survival of Probiotic Bacterial Cells in the Upper Gastrointestinal Tract and the Effect of the Surviving Population on the Colonic Microbial Community Activity and Composition. Nutrients. 2024;16(8):2791. doi: 10.3390/nu16162791.

  • Magnesium in Human Health and Disease: A Review of Our Current Understanding

    • Author(s): Harry Jarrett, Ryan McNally, Anna Hernández-Rubio, Sally Brett, Luca Faconti
    • Year: 2024
    • Citation: Jarrett H, McNally R, Hernández-Rubio A, Brett S, Faconti L. Magnesium in Human Health and Disease: A Review of Our Current Understanding. EC Nutrition. 2024;23(7):2303-2315.

  • Association of dietary flavan-3-ol intakes with plasma phenyl-γ-valerolactones: analysis from the TUDA cohort of healthy older adults

    • Author(s): Donato Angelino, Aoife Caffrey, Helene McNulty, Chris IR. Gill, Pedro Mena, Alice Rosi, Katie Moore, Leane Hoey, Michelle Clements, Eamon Laird, et al.
    • Year: 2023
    • Citation: Angelino D, Caffrey A, McNulty H, Gill CIR, Mena P, Rosi A, Moore K, Hoey L, Clements M, Laird E, et al. Association of dietary flavan-3-ol intakes with plasma phenyl-γ-valerolactones: analysis from the TUDA cohort of healthy older adults. Am J Clin Nutr. 2023;118(2):426-438. doi: 10.1016/j.ajcnut.2023.06.006.

  • Vitamin B-6 and riboflavin, their metabolic interaction, and relationship with MTHFR genotype in adults aged 18-102 years

    • Author(s): Harry Jarrett, Helene McNulty, Catherine Hughes, Kristina Pentieva, James J. Strain, Anne Molloy, Aileen McCann, et al.
    • Year: 2022
    • Citation: Jarrett H, McNulty H, Hughes CF, Pentieva K, Strain JJ, Molloy A, McCann A, et al. Vitamin B-6 and riboflavin, their metabolic interaction, and relationship with MTHFR genotype in adults aged 18-102 years. Am J Clin Nutr. 2022;116(6):1422-1431. doi: 10.1093/ajcn/nqac240.

  • Validity of plasma phenyl-γ-valerolactones as novel biomarkers of dietary (poly)phenols: Preliminary analysis from the VALID project

    • Author(s): B. Parmenter, K. Moore, D. Angelino, D. Del Rio, H. McNulty, A.M. Molloy, C. Cunningham, M. Ward, B. Pucci, H. Jarrett, et al.
    • Year: 2018
    • Citation: Parmenter B, Moore K, Angelino D, Del Rio D, McNulty H, Molloy AM, Cunningham C, Ward M, Pucci B, Jarrett H, et al. Validity of plasma phenyl-γ-valerolactones as novel biomarkers of dietary (poly)phenols: Preliminary analysis from the VALID project. Proc Nutr Soc. 2018;77(3):234-243. doi: 10.1017/s0029665118001040.

  • Blood pressure and hypertension in relation to cognitive performance in older Irish adults from the TUDA cohort: Preliminary analysis

    • Author(s): Harry Jarrett
    • Year: 2018
    • Citation: Jarrett H. Blood pressure and hypertension in relation to cognitive performance in older Irish adults from the TUDA cohort: Preliminary analysis. J Hum Hypertens. 2018;32(5):319-326. doi: 10.1038/s41371-018-0089-5.

  • Effect of B-vitamin Supplementation on Cognitive Performance and Brain Function in The BrainHOP Trial

    • Author(s): Katie Moore, Catherine Hughes, Kirsty Porter, Leanne Doherty, Pramod Gaur, Fergal Tracey, Maurice O’Kane, Harry Jarrett, Mary Ward, Leanne Hoey
    • Year: 2018
    • Citation: Moore K, Hughes C, Porter K, Doherty L, Gaur P, Tracey F, O’Kane M, Jarrett H, Ward M, Hoey L. Effect of B-vitamin Supplementation on Cognitive Performance and Brain Function in The BrainHOP Trial. Age Ageing. 2018;47(5):702-710. doi: 10.1093/ageing/afy141.35.

 

Ravivats | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Posted on by ScienceFather

Dr. Ravi vats | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Scientist at Q32 bio, United States

Dr. Ravi Vats is a passionate scientist specializing in pharmacology, currently working as a Scientist 1 at Q32 Bio Inc. in Waltham, MA, USA. He holds a wealth of experience in assay validation, technology transfer, and biomarker evaluation in clinical trials. His research career began at the University of Pittsburgh, where he made significant contributions to studies involving sickle cell disease and its complications. Over the years, he has honed his expertise in advanced imaging techniques, including intravital imaging, and artificial intelligence-based digital image analysis. Throughout his career, Dr. Vats has been committed to bridging the gap between experimental research and its clinical applications, with a strong focus on drug development. His collaborative work across various research teams and partnerships with external organizations, including vendors and CROs, has positioned him as a key figure in his field. Dr. Vats is known for his dedication, innovative approaches, and contributions to biomedical research.

Professional Profile

Education

Dr. Ravi Vats earned his PhD in pharmacology from the University of Pittsburgh’s Vascular Medicine Institute (VMI). His doctoral research focused on the pathophysiology of sickle cell disease (SCD), investigating mechanisms like platelet aggregation and vaso-occlusion, with notable work on drug interventions for managing SCD complications. Prior to his PhD, Dr. Vats obtained a Bachelor’s degree in a relevant field, where he laid the foundation for his career in biomedical research. Throughout his academic journey, he worked alongside esteemed scientists, contributing to projects that explored the role of inflammation, blood cell interactions, and vascular health. Dr. Vats has continuously developed his scientific knowledge through his post-doctoral studies and professional roles. His academic background has provided him with a solid theoretical and practical foundation in molecular pharmacology, translational research, and preclinical drug development, making him well-equipped to tackle complex scientific challenges in his field.

Professional Experience

Dr. Vats’ professional journey includes roles at prominent pharmaceutical and research institutions, demonstrating a progressive career in pharmacology and biomedical research. Since November 2022, he has been a Scientist 1 at Q32 Bio, where he supports drug development through preclinical pharmacology studies and leads biomarker evaluations for clinical trials. Previously, he worked at Forma Therapeutics, where he independently designed and executed biomarker studies. His earlier postdoctoral work at the University of Pittsburgh’s Vascular Medicine Institute involved evaluating new drug candidates for sickle cell disease, particularly CSL889, during vaso-occlusive crises. As a graduate student, Dr. Vats published numerous influential research papers, contributing to high-impact journals. He also served as an imaging specialist at the VMI, developing expertise in advanced imaging techniques like multi-photon fluorescence microscopy. Throughout his career, Dr. Vats has collaborated with CROs, vendors, and internal stakeholders, showcasing his leadership and ability to manage complex research projects.

Research Interests

Dr. Ravi Vats’ primary research interests focus on the pharmacology of vascular diseases, with a particular emphasis on sickle cell disease (SCD) and related complications. His work has investigated the mechanisms underlying blood vessel occlusion, platelet aggregation, and inflammation, which are key drivers in diseases like SCD. He is also deeply interested in exploring the role of biomarkers in drug development, particularly in the context of validating new therapeutic targets. Dr. Vats’ expertise extends to the use of advanced imaging techniques, including intravital imaging and digital analysis, to gain deeper insights into disease pathogenesis and to assess therapeutic efficacy. Furthermore, he is actively involved in evaluating novel technologies for use in research and clinical trials. By focusing on both basic and translational research, Dr. Vats aims to contribute to the development of more effective treatments for complex diseases, bridging the gap between preclinical findings and clinical applications.

Awards and Honors

Throughout his distinguished career, Dr. Ravi Vats has earned recognition for his contributions to pharmacology and biomedical research. He has been a key contributor to several collaborative projects that have led to publications in high-impact journals, earning him acknowledgment within the scientific community. His work on sickle cell disease has been highlighted in publications like JCI Insight, where he was a co-author of research on lung vaso-occlusion and micro emboli. Although specific awards and honors are not detailed in the provided profile, his academic journey and professional accomplishments indicate his reputation within the scientific community. Dr. Vats has also received numerous opportunities to work at esteemed institutions and with global leaders in pharmacology, underscoring his expertise and value in advancing clinical research. His involvement in high-level projects and studies suggests that he is a respected figure in the areas of pharmacology, biomarker research, and drug development.

Conclusion

Dr. Ravi Vats is undoubtedly a strong candidate for the Best Researcher Award. His work in biomarker studies, assay validation, and innovative technology application, coupled with his leadership in coordinating research efforts, makes him a standout researcher in his field. By expanding his publication portfolio and increasing his public and translational research efforts, he could further strengthen his profile and make an even larger impact on the scientific and medical community. Based on his current achievements, he has proven himself as an exceptional researcher with the potential to continue making groundbreaking contributions in pharmacology and disease research.

Publications Top Noted

  • Subcutaneous injection of IHP-102 prevents lung vaso-occlusion in sickle cell disease mice
    • Authors: Dubey, R.K., Vats, R., Brzoska, T., Paderi, J., Sundd, P.
    • Journal: Haematologica, 2024, 109(4), pp. 1259–1263
    • Citations: 0
  • Lung microvascular occlusion by platelet-rich neutrophil-platelet aggregates promotes cigarette smoke-induced severe flu
    • Authors: Kaminski, T.W., Brzoska, T., Li, X., Nyunoya, T., Sundd, P.
    • Journal: JCI Insight, 2024, 9(2), e167299
    • Citations: 6
  • Liver-to-lung microembolic NETs promote gasdermin D–dependent inflammatory lung injury in sickle cell disease
    • Authors: Vats, R., Kaminski, T.W., Brzoska, T., Gladwin, M.T., Sundd, P.
    • Journal: Blood, 2022, 140(9), pp. 1020–1037
    • Citations: 43
  • Defenestrated endothelium delays liver-directed gene transfer in hemophilia A mice
    • Authors: Kaminski, T.W., Ju, E.-M., Gudapati, S., Sundd, P., Pradhan-Sundd, T.
    • Journal: Blood Advances, 2022, 6(12), pp. 3729–3734
    • Citations: 4
  • Intravital imaging reveals inflammation as a dominant pathophysiology of age-related hepatovascular changes
    • Authors: Vats, R., Li, Z., Ju, E.-M., Watkins, S., Pradhan-Sundd, T.
    • Journal: American Journal of Physiology – Cell Physiology, 2022, 322(3), pp. C508–C520
    • Citations: 6
  • Single cell RNA sequencing identifies IGFBP5 and QKI as ciliated epithelial cell genes associated with severe COPD
    • Authors: Li, X., Noell, G., Tabib, T., Faner, R., Nyunoya, T.
    • Journal: Respiratory Research, 2021, 22(1), 100
    • Citations: 17
  • Intravital Imaging of Hepatic Blood Biliary Barrier in Live Mice
    • Authors: Vats, R., Kaminski, T.W., Pradhan-Sundd, T.
    • Journal: Current Protocols, 2021, 1(10), e256
    • Citations: 5
  • Compensatory hepatic adaptation accompanies permanent absence of intrahepatic biliary network due to YAP1 loss in liver progenitors
    • Authors: Molina, L.M., Zhu, J., Li, Q., Bell, A., Monga, S.P.
    • Journal: Cell Reports, 2021, 36(1), 109310
    • Citations: 22
  • P-selectin deficiency promotes liver senescence in sickle cell disease mice
    • Authors: Vats, R., Kaminski, T.W., Ju, E.-M., Sundd, P., Pradhan-Sundd, T.
    • Journal: Blood, 2021, 137(19), pp. 2676–2680
    • Citations: 11
  • Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease
    • Authors: Vats, R., Liu, S., Zhu, J., Monga, S.P., Pradhan-Sundd, T.
    • Journal: Hepatology, 2020, 72(6), pp. 2165–2181
    • Citations: 15